

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司\*

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 00858)

### RETIREMENT OF AUDITOR AND WITHDRAWAL OF RESOLUTION AT THE ANNUAL GENERAL MEETING TO BE HELD ON 23 AUGUST 2024

#### RETIREMENT OF AUDITOR

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”) pursuant to rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (the “**Board**”) of the Company announces that the Company has received a formal notice from Elite Partners CPA Limited (“**Elite Partners**”) that Elite Partners, after considering factors including their available internal resources, decided not to offer themselves for re-appointment as the auditor of the Company (the “**Auditor**”) at the forthcoming annual general meeting of the Company to be held on 23 August 2024 (the “**AGM**”) and will retire as Auditor upon expiration of its current term of office at the conclusion of the AGM (the “**Retirement of Auditor**”).

The Company has received the confirmation from Elite Partners that there are no matters in relation to its retirement that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”). The Board and the audit committee of the Company have also confirmed that there is no disagreement between Elite Partners and the Company, and there are no other matters in respect of the Retirement of Auditor that need to be brought to the attention of the Shareholders.

The Board is in the process of identifying a suitable Auditor to fill the casual vacancy arising from the Retirement of Auditor. Further announcement in relation to the appointment of new Auditor will be made by the Company as soon as practicable.

The Board would like to take this opportunity to express its gratitude to Elite Partners for its professional services rendered to the Company during the past years.

## **WITHDRAWAL OF AGM RESOLUTION**

Reference is made to the circular of the Company dated 29 July 2024 which includes a notice of the AGM (the “**Notice**”). Pursuant to the agenda of the Notice, ordinary resolution numbered 3 (“**Resolution (3)**”) proposed to re-appoint the independent Auditor and to authorise the Board to fix its remuneration. In light of the Retirement of Auditor, the Board announces that it decided to withdraw Resolution (3) from the agenda of the AGM.

The withdrawal of Resolution (3) does not affect the validity of the Notice, the proxy form or any proxy votes already submitted in respect of the remaining resolutions to be proposed at the AGM. The numbering of all other proposed resolutions at the AGM remains unchanged.

Arrangements for the AGM are unchanged from those previously notified.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 12 August 2024

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.*

\* *For identification purpose only*